Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Protara Therapeutics, Inc. (NASDAQ:TARA) has received a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $19.50.

A number of brokerages have weighed in on TARA. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a report on Wednesday, December 3rd.

Protara Therapeutics Price Performance

NASDAQ TARA opened at $5.27 on Monday. Protara Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.82. The firm has a market capitalization of $272.09 million, a PE ratio of -3.69 and a beta of 1.38. The company’s 50 day simple moving average is $5.73 and its 200 day simple moving average is $4.19.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. Sell-side analysts anticipate that Protara Therapeutics will post -3.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Protara Therapeutics

Several hedge funds have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey purchased a new position in Protara Therapeutics in the 2nd quarter worth about $30,000. Quadrature Capital Ltd acquired a new position in shares of Protara Therapeutics in the second quarter worth about $35,000. JPMorgan Chase & Co. purchased a new position in shares of Protara Therapeutics in the second quarter worth approximately $46,000. Los Angeles Capital Management LLC acquired a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $47,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $49,000. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.